...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Financials
8
Apr 07, 2020 04:10PM
1
Apr 09, 2020 07:28PM

At January 31, Zenith owed RVX $0.96 million. At October 31, it owed $1.21 million. I don't remember exactly how this debt initiated but one can't solely look at the change in the amount owing and say that is what was paid. There is also another $300,000 that accrues each year for rent and operating costs that must be paid to RVX for sharing their offices and labs. This can't be isolated in RVX's statements as it is recorded as recoveries of R&D or G&A expenses. Their statements just show -R&D, net of recoveries - or G&A, net of recoveries.

Share
New Message
Please login to post a reply